• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Silk Road Medical Reports Second Quarter 2024 Financial Results

    8/7/24 4:05:00 PM ET
    $BSX
    $SILK
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024.

    "Our solid second quarter performance demonstrates continued TCAR adoption and growth driven by the unwavering dedication of our team," said Chas McKhann, CEO of Silk Road Medical. "We look forward to continuing our mission as part of Boston Scientific and, together, expanding patient access to our minimally invasive approach to stroke prevention."

    Second Quarter 2024 Financial Results

    Revenue for the second quarter of 2024 was $51.2 million, an increase of $5.9 million or 13%, compared to the second quarter of 2023.

    Gross profit for the second quarter of 2024 was $38.5 million compared to $32.3 million for the second quarter of 2023. Gross margin was 75% for the second quarter of 2024 compared to 71% in the second quarter of 2023.

    Operating expenses were $55.7 million for the second quarter of 2024, compared to $46.6 million in the comparable prior year period, an increase of 20%.

    Net loss was $16.6 million in the second quarter of 2024, or $0.42 per share, as compared to a loss of $13.5 million, or $0.35 per share, in the corresponding period of the prior year.

    Adjusted EBITDA was a loss of $1.1 million for the second quarter of 2024 compared to a loss of $3.4 million for the second quarter of 2023. For additional information regarding non-GAAP financial measures see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA" below.

    Cash, cash equivalents and investments were $186.2 million as of June 30, 2024.

    2024 Financial Guidance

    Given the proposed acquisition of Silk Road Medical by Boston Scientific Corporation (NYSE:BSX), the Company is withdrawing its prior full year 2024 financial guidance.

    About Silk Road Medical

    Silk Road Medical, Inc. (NASDAQ:SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on X, LinkedIn and Facebook.

    Forward-Looking Statements

    Statements contained in this press release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995, including Silk Road Medical's financial guidance and statements related to the future opportunity of its business. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "expect," "should," "project," "anticipate," "intend," "will," "can," "may," "believe," "could," "continue," "outlook," "guidance," "future," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause Silk Road Medical's actual results to be materially different than those expressed in or implied by Silk Road Medical's forward-looking statements. For Silk Road Medical, such risks and uncertainties include, among others, risks and uncertainties relating to the Company's proposed merger with Boston Scientific Corporation, including without limitation the risk that the merger may not be completed on the anticipated timeline or at all or the effect of the announcement or pendency of the merger on the Company's business relationships, operating results and business generally and ability to retain and hire key personnel and maintain relationships with key business partners, customers and others with whom it does business; future operating results and financial performance; the Company's success in retaining and recruiting key personnel; the ability to continue to grow the business and expand the use of TCAR; the ability to obtain an adequate supply of materials and components from its third-party suppliers; product development plans and the ability to commercialize new products in a timely manner; the success of current clinical trials; plans to conduct further clinical trials; the ability to obtain additional indications or new regulatory approvals or clearances for its products; market acceptance and use of its products by physicians; the ability to grow and leverage its commercialization infrastructure; the effect of increased competition; the effect of economic conditions and COVID-19 or similar pandemics on its business; government and third-party payer coverage and reimbursement and the ability to obtain and maintain intellectual property protection for its products. More detailed information on these and other factors that could affect Silk Road Medical's actual results are described in its filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024. Silk Road Medical undertakes no obligation to update its forward-looking statements.

    Use of Non-GAAP Financial Measures

    To supplement its financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), Silk Road Medical uses adjusted EBITDA, which is a non-GAAP financial measure, in this press release. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss, which is the most directly comparable GAAP financial measure, is provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation. Non-GAAP adjusted EBITDA is calculated by adding back to net loss or excluding, as appropriate, interest income and expense, provision for income taxes, and charges for depreciation and amortization and is further adjusted by adding back in or excluding, as appropriate, other income and expense, stock-based compensation and acquisition-related costs. Silk Road Medical believes the presentation of adjusted EBITDA provides useful information to investors as it provides visibility to its underlying continuing operating performance from period to period by excluding the impact of certain items that are non-cash or non-recurring in nature or not related to its core business operations. Adjusted EBITDA is also frequently used by analysts, investors and other interested parties to evaluate companies in the same industry. Management uses adjusted EBITDA internally for evaluation of the performance of its business, including the allocation of resources.

    Silk Road Medical's definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered only as a supplement to, and not as a substitute for, or superior to, net income or loss prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease Silk Road Medical's reported results of operations, management strongly encourages investors to review, when they become available, its financial statements and publicly filed SEC reports in their entirety.

    Investor Contact:

    Marissa Bych

    Gilmartin Group

    [email protected]

    Media:

    Michael Fanucchi

    Silk Road Medical

    [email protected]



    SILK ROAD MEDICAL, INC.
    Statements of Operations Data
    (unaudited, in thousands, except share and per share data)
     
     Three Months Ended Six Months Ended
     June 30, June 30,
     2024  2023  2024  2023 
    Revenue$51,242  $45,298  $99,726  $85,429 
    Cost of goods sold 12,736   13,004   24,719   25,530 
    Gross profit 38,506   32,294   75,007   59,899 
    Operating expenses:           
    Research and development 11,883   10,780   22,543   21,213 
    Selling, general and administrative 43,818   35,830   84,593   69,913 
    Total operating expenses 55,701   46,610   107,136   91,126 
    Loss from operations (17,195)  (14,316)  (32,129)  (31,227)
    Interest income 2,321   2,434   4,792   4,721 
    Interest expense (1,725)  (1,712)  (3,445)  (3,405)
    Other income (expense), net (4)  110   43   (33)
    Net loss (16,603)  (13,484)  (30,739)  (29,944)
    Other comprehensive loss:           
    Unrealized loss on investments, net (105)  (414)  (194)  (165)
    Other comprehensive income loss (105)  (414)  (194)  (165)
                
    Comprehensive loss$(16,708) $(13,898) $(30,933) $(30,109)
                
    Net loss per share, basic and diluted$(0.42) $(0.35) $(0.78) $(0.77)
                
    Weighted average common shares used to compute net loss per share, basic and diluted 39,620,888   38,765,166   39,441,192   38,649,327 



    SILK ROAD MEDICAL, INC.

    Balance Sheets Data

    (unaudited, in thousands)

           
     June 30, 2024 December 31, 2023
    Assets     
    Current assets     
    Cash and cash equivalents$22,639  $20,210 
    Short-term investments 149,344   161,264 
    Accounts receivable, net 26,252   23,573 
    Inventories 29,682   29,876 
    Prepaid expenses and other current assets 13,104   5,912 
    Total current assets 241,021   240,835 
    Long-term investments 14,178   9,456 
    Property and equipment, net 8,381   8,114 
    Other non-current assets 6,227   6,904 
    Total assets$269,807  $265,309 
    Liabilities and stockholders' equity     
    Current liabilities     
    Accounts payable$3,693  $5,676 
    Accrued liabilities 27,879   24,607 
    Total current liabilities 31,572   30,283 
    Long-term debt 76,147   75,626 
    Other liabilities 7,404   8,249 
    Total liabilities 115,123   114,158 
    Stockholders' equity     
    Preferred stock, $0.001 par value —   — 
    Common stock, $0.001 par value 41   39 
    Additional paid-in capital 584,959   550,495 
    Accumulated other comprehensive income (loss) (122)  72 
    Accumulated deficit (430,194)  (399,455)
    Total stockholders' equity 154,684   151,151 
    Total liabilities and stockholders' equity$269,807  $265,309 



    SILK ROAD MEDICAL, INC.

    Reconciliation of GAAP Net Loss to Adjusted EBITDA

    (unaudited, in thousands)
     
     Three Months Ended Six Months Ended
     June 30, June 30,
     2024 2023 2024 2023

    GAAP Net Loss$(16,603) $(13,484) $(30,739) $(29,944)
    Non-GAAP Adjustments:           
    Interest (income) expense, net (596)  (722)  (1,347)  (1,316)
    Depreciation and amortization 665   685   1,309   1,384 
    Other (income) expense, net 4   (110)  (43)  33 
    Stock-based compensation expense 11,040   10,198   21,399   19,037 
    Acquisition-related costs 4,382   —   4,382   — 
    Adjusted EBITDA$(1,108) $(3,433) $(5,039) $(10,806)


    Primary Logo

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSX
    $SILK

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Silk Road Medical Inc.
    $SILK
    7/11/2024Buy → Sell
    Argus
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Silk Road Medical Inc.
    $SILK
    3/7/2024$24.00Hold → Buy
    Argus
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    More analyst ratings

    $BSX
    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and CFO Monson Jonathan

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:43 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 50,000 shares at a strike of $26.15 and sold $5,348,315 worth of shares (50,000 units at $106.97) (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SVP, GC and Corp. Secretary Brown Vance R converted options into 4,036 shares and covered exercise/tax liability with 1,952 shares, increasing direct ownership by 7% to 33,451 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:38 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

      The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

      7/7/25 7:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

      1/10/25 8:51:50 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    SEC Filings

    See more
    • SEC Form 11-K filed by Boston Scientific Corporation

      11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      6/18/25 5:14:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Corporation filed SEC Form 8-K: Other Events

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/28/25 7:45:47 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Boston Scientific Corporation

      SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/22/25 4:10:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

      BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

      1/6/25 9:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for first quarter 2025

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

      4/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing first quarter 2025 results

      MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

      4/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care